Farmakoterapia w Psychiatrii i Neurologii

Pełna treść

2/2025 vol. 41
Opis przypadku

Potencjalizacja leczenia przeciwdepresyjnego racemiczną ketaminą u pacjenta z epizodem ciężkiej depresji w przebiegu choroby afektywnej dwubiegunowej (ChAD) i pozytywnym wywiadem w kierunku manii psychotycznej – opis przypadku

Gracja Ryznar 1
,
Katarzyna M. Bliźniewska-Kowalska 1
,
Piotr Gałecki 1
  1. Department of Adult Psychiatry, Medical University of Lodz, Poland; Klinika Psychiatrii Dorosłych Uniwersytetu Medycznego w Łodzi, Łodź, Polska
Farmakoterapia w Psychiatrii i Neurologii 2025
DOI: https://doi.org/10.5114/fpn.2025.159505
Data publikacji online: 2026/04/28
Plik artykułu
Potentiation of antidepressant treatment with racemic ketamine in a patient with an episode of sever
Confronting perimenopausal women’s knowledge of coronary heart disease with their health behaviours. Controversial role of hormone replacement therapy in the protection of coronary heart disease
  1. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch. Gen. Psychiatry 2000; 57: 270–276.
  2. Berk M, Post R, Ratheesh A, Gliddon E, Singh A, Vieta E et al. Staging in bipolar disorder: from theoretical framework to clinical utility. World Psychiatry 2017; 16: 236–244.
  3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS et al. Antidepressant effects of ketamine in depressed patients. Biol. Psychiatry 2000; 47: 351–354.
  4. Chakrabarti S, Singh N. Psychotic symptoms in bipolar disorder and their impact on the illness: A systematic review. World J Psychiatry 2022; 12: 1204–1232.
  5. Correa R, Akiskal H, Gilmer W, Nierenberg AA, Trivedi M, Zisook S. Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? J. Affect. Disord. 2010; 127: 10–18.
  6. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 2010; 67: 793–802.
  7. European Medicines Agency. Annex and Summary of Product Characteristics; https://www.ema.europa.eu/en/documents/product-information/spravato-epar-product-information_en.pdf (dostęp 22.12.2025).
  8. Fancy F, Rodrigues NB, Di Vincenzo JD, Chau EH, Sethi R, Husain MI et al. Real-world effectiveness of repeated ketamine infusions for treatment-resistant bipolar depression. Bipolar Disorder 2023; 25: 99–109.
  9. Feeney A, Hoeppner BB, Freeman MP, Flynn M, Iosifescu DV, Trivedi MH et al. Effect of Concomitant Benzodiazepines on the Antidepressant Effects of Ketamine: Findings From the RAPID Intravenous Ketamine Study. J. Clin. Psychiatry 2022; 84.
  10. Gałecki P, Bliźniewska-Kowalska KM, Cubała WJ, Depukat A, Mosiołek A, Rybakowski J et al. Polski standard leczenia racemiczną ketaminą pacjentów z zaburzeniami depresyjnymi opracowany przez zespół roboczy powołany przez Konsultanta Krajowego w dziedzinie psychiatrii. Psychiatr. Pol. 2024; 58: 377–401.
  11. Goddard K, Sampson C, Bedy SM, Ghadban R, Stilley J. Effect of Ketamine on Cardiovascular Function During Procedural Sedation of Adults. Cureus 2021; 13: e14228.
  12. Grunze H, Born C. The Impact of Subsyndromal Bipolar Symptoms on Patient's Functionality and Quality of Life. Front Psychiatry 2020; 11: 510.
  13. Gutowska-Ibbs AM, Permoda-Pachuta A, Karakuła-Juchnowicz H. An analysis of the fulfilment criteria for a medical experiment with regards to the use of intravenous ketamine in the treatment of drug-resistant depression. Current Problems of Psychiatry 2023; 24: 76–86.
  14. Jawad MY, Qasim S, Ni M, Guo Z, Di Vincenzo JD, d'Andrea G et al. The Role of Ketamine in the Treatment of Bipolar Depression: A Scoping Review. Brain Sci 2023; 13.
  15. Jelen LA, Stone JM. Ketamine for depression. Int. Rev. Psychiatry 2021; 33: 207–228.
  16. Kachlik Z, Cubała WJ, Walaszek M, Pastuszak M, Pastuszak K, Kwaśny A. Nonresponse to Ketamine in Treatment-Resistant Bipolar Depression. Neuropsychopharmacology Reports 2025; 45: e70038.
  17. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA. Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transl Psychiatry 2014; 4: e469.
  18. Lima Constantino J, Godschalk M, van Dalfsen JH, Veraart JKE, Spijker J, van Exel E et al. Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review. Psychiatry Res. 2025; 345: 116355.
  19. Liu TH, Wu JY, Huang PY, Cheng WL, Lai CC. Risk of manic switch and suicidal outcomes in bipolar depression treated with esketamine: A one-year retrospective cohort study of 2126 patients. Eur. Neuropsychopharmacol. 2025; 99: 3–12.
  20. Marcinowicz P, Więdłocha M, Dębowska W, Dębowska M, Szulc A. Racemiczna ketamina w leczeniu depresji lekoopornej. Medycyna Praktyczna. Psychiatria 2024; 1: 52–66.
  21. Martinotti G, Dell'Osso B, Di Lorenzo G, Maina G, Bertolino A, Clerici M et al. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression. Bipolar Disorder 2023; 25: 233–244.
  22. Murrough JW, Soleimani L, DeWilde KE, Collins KA, Lapidus KA, Iacoviello BM et al. Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial. Psychol. Med. 2015; 45: 3571–3580.
  23. National Institute of Mental Health. About RDoC; https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/about-rdoc (dostęp 23.12.2025).
  24. Oliva V, Fico G, De Prisco M, Gonda X, Rosa AR, Vieta E. Bipolar disorders: an update on critical aspects. Lancet Reg Health Eur 2025; 48.
  25. Pennybaker SJ, Luckenbaugh DA, Park LT, Marquardt CA, Zarate CA, Jr. Ketamine and Psychosis History: Antidepressant Efficacy and Psychotomimetic Effects Postinfusion. Biol. Psychiatry 2017; 82: e35–e36.
  26. Santucci MC, Ansari M, Nikayin S, Radhakrishnan R, Rhee TG, Wilkinson ST. Efficacy and Safety of Ketamine/Esketamine in Bipolar Depression in a Clinical Setting. J. Clin. Psychiatry 2024; 85.
  27. Sharma V, Khan M, Smith A. A closer look at treatment resistant depression: is it due to a bipolar diathesis? J. Affect. Disord. 2005.; 84: 251–257.
  28. Shen Z, Gao D, Lv X, Wang H, Yue W. A meta-analysis of the effects of ketamine on suicidal ideation in depression patients. Transl Psychiatry 2024; 14: 248.
  29. Shiroma PR, Thuras P, Wels J, Albott CS, Erbes C, Tye S et al. A randomized, double-blind, active placebo-controlled study of efficacy, safety, and durability of repeated vs single subanesthetic ketamine for treatment-resistant depression. Transl Psychiatry 2020; 10: 206.
  30. Singh B, Swartz HA, Cuellar-Barboza AB, Schaffer A, Kato T, Dols A et al. Bipolar disorder. Lancet 2025; 406: 963–978.
  31. Spiegel D, Loewenstein RJ, Lewis-Fernández R, Sar V, Simeon D, Vermetten E et al. Dissociative disorders in DSM-5. Depress. Anxiety 2011; 28: 824–852.
  32. Szarmach J, Cubała WJ, Włodarczyk A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub 2019; 31: 585–590.
  33. U.S. Food and Drug Administration. Highlights of Prescribing Information; https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf (dostęp 23.12.2025).
  34. Veraart JKE, Smith-Apeldoorn SY, Spijker J, Kamphuis J, Schoevers RA. Ketamine Treatment for Depression in Patients With a History of Psychosis or Current Psychotic Symptoms: A Systematic Review. J. Clin. Psychiatry 2021; 82.
  35. Vieta E, McIntyre RS, Suppes T, Van Rheenen TE, Singh B, Miskowiak KW et al. Defining Treatment-Resistant Bipolar Depression: Recommendations From the ISBD Task Force. Bipolar Disorder 2025; 27: 411–423.
  36. Walaszek M, Cubała WJ, Kachlik Z, Pastuszak M, Pastuszak K, Kwaśny A. Non-response to short-term ketamine use for treatment-resistant depression. Pharmacol. Rep. 2025; 77: 1126–1133.
  37. Wang C, Lan X, Liu W, Zhan Y, Zheng W, Chen X et al. Non-improvement predicts subsequent non-response to repeated-dose intravenous ketamine for depression: a re-analysis of a 2-week open-label study in patients with unipolar and bipolar depression. Transl Psychiatry 2024; 14: 324.
  38. Wilkhoo HS, Islam AW, Reji F, Sanghvi L, Potdar R, Solanki S. Depersonalization-Derealization Disorder: Etiological Mechanism, Diagnosis and Management. Discoveries (Craiova) 2024; 12: e190.
  39. Wilkowska A, Cubała WJ. The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine. Int. J. Mol. Sci. 2022; 23.
  40. Wilkowska A, Cubała WJ. Short-term ketamine use in bipolar depression: a review of the evidence for short-term treatment management. Front Psychiatry 2023; 14: 1322752.
ZGŁASZANIE PRAC
Udostępnij
without publication fees
without publication fees
Zintergrowane z
Zasady redakcyjne
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications